Fulgent Genetics, Inc.
For the period ended Mar 31, 2026. Filed May 1, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 1, 2026
FLGT$26.15+10.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenue | $71,138 | $73,463 |
| Cost of revenue | 49,648 | 45,117 |
| Gross profit | 21,490 | 28,346 |
| Operating expenses | ||
| Research and development | 14,176 | 12,395 |
| Selling and marketing | 12,221 | 8,465 |
| General and administrative | 27,684 | 25,291 |
| Amortization of intangible assets | 2,031 | 1,990 |
| Total operating expenses | 56,112 | 48,141 |
| Operating loss | (34,622) | (19,795) |
| Other income (expenses) | ||
| Interest income | 8,651 | 8,018 |
| Interest expense | (17) | (14) |
| Other income, net | 10 | 68 |
| Total other income, net | 8,644 | 8,072 |
| Loss before income taxes | (25,978) | (11,723) |
| (Benefit from) provision for income taxes | (704) | 176 |
| Net loss from consolidated operations | (25,274) | (11,899) |
| Net loss attributable to noncontrolling interests | 448 | 369 |
| Net loss attributable to Fulgent | $(24,826) | $(11,530) |
| Net loss per common share attributable to Fulgent | ||
| Basic | $(0.80) | $(0.37) |
| Diluted | $(0.80) | $(0.37) |
| Weighted-average common shares: | ||
| Basic | 30,881 | 30,832 |
| Diluted | 30,881 | 30,832 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.